September 2020, Drugs Monitor

(27 Sep 2020) Tocilizumab- associated with a lower risk of death or ICU or death in patients with higher CRP levels

September 29, 2020

Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A multicenter cohort study https://doi.org/10.1016/j.cmi.2020.09.021 A total of 1,229 patients were analyzed, with 261 patients (61 deaths) in the tocilizumab group and 969 patients (120 deaths) in the control group.… Continue reading "(27 Sep 2020) Tocilizumab- associated with a lower risk of death or ICU or death in patients with higher CRP levels"

(25 Sep 2020) Corticosteroids- less mortality in severe patients compared to critical patients

September 26, 2020

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study. https://doi.org/10.1016/j.cmi.2020.09.014 Of 1717 patients with COVID-19 evaluated, 513 patients were included in the study; of these 170 (33%) were treated with corticosteroids. During the hospitalization 166 (34%)… Continue reading "(25 Sep 2020) Corticosteroids- less mortality in severe patients compared to critical patients"

(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters

September 26, 2020

The effects of favipiravir on hematological parameters of covid-19 patients. https://doi.org/10.1590/1806-9282.66.S2.65 Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. The mean age of the patients receiving treatment with favipiravir was 63.7+/-12.3… Continue reading "(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters"

(23 Sep 2020) Tinospora Cordifolia- proven to be effective in asymptomatic patients

September 26, 2020

Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 infection: An Open Label Feasibility Study https://www.medrxiv.org/content/10.1101/2020.09.20.20198515v1 An open label, feasibility trial (NCT04542876)was conducted on 46 patients in the hospital setting. A single-arm study with no control… Continue reading "(23 Sep 2020) Tinospora Cordifolia- proven to be effective in asymptomatic patients"

(21 Sep 2020) Hydroxychloroquine- Pre-exposure prophylaxis with HCQ did not significantly reduce laboratory-confirmed Covid-19

September 22, 2020

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1 A randomized, double-blind, placebo-controlled clinical trial (NCT04328467) of healthcare workers with ongoing exposure to persons with Covid-19 was conducted. Participants across the United States and in the… Continue reading "(21 Sep 2020) Hydroxychloroquine- Pre-exposure prophylaxis with HCQ did not significantly reduce laboratory-confirmed Covid-19"

(18 Sep 2020) Corticosteroids- not beneficial at later stage in old population

September 19, 2020

Association between corticosteroids and intubation or death among patients with COVID-19 pneumonia in non-ICU settings: an observational study using of real-world data from 51 hospitals in France and Luxembourg https://www.medrxiv.org/content/10.1101/2020.09.16.20195750v1 Among the 891 patients included in the analysis, 203 were… Continue reading "(18 Sep 2020) Corticosteroids- not beneficial at later stage in old population"

(15 Sep 2020) Hydroxychloroquine & Azithromycin- associated with reduced in-hospital mortality in patients

September 17, 2020

Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients https://doi.org/10.1111/cts.12860 A retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease (COVID-19) was conducted. Of these 297 were in combination treatment,… Continue reading "(15 Sep 2020) Hydroxychloroquine & Azithromycin- associated with reduced in-hospital mortality in patients"

(14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration

September 17, 2020

A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients https://doi.org/10.1016/j.jcrc.2020.08.025 In this observational cohort study, patients >/=18 years with COVID-19 admitted to an ICU at one institution from March… Continue reading "(14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration"

(13 Sep 2020) Hydroxychloroquine- Early intervention with HCQ-based therapy is associated with lower adverse clinical outcomes

September 15, 2020

The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study https://www.medrxiv.org/content/10.1101/2020.09.09.20184143v1 Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever clinics during the study period, 5,541 had verified clinical… Continue reading "(13 Sep 2020) Hydroxychloroquine- Early intervention with HCQ-based therapy is associated with lower adverse clinical outcomes"

(13 Sep 2020) Anakinra & Tocilizumab- associated with improved clinical outcomes

September 15, 2020

Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia https://www.medrxiv.org/content/10.1101/2020.09.11.20192401v1 84 consecutive patients who received either treatment (51 in the Anakinra/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar… Continue reading "(13 Sep 2020) Anakinra & Tocilizumab- associated with improved clinical outcomes"

Month: September 2020